Thrivent Mid Cap Value ETF (TMVE)

The Thrivent Mid Cap Value ETF (NASDAQ: TMVE) is an exchange-traded fund that holds medium-sized U.S. companies selected by Thrivent Financial’s investment team according to a value-investing philosophy — seeking businesses that trade below the team’s estimate of intrinsic worth, with an added layer of screening for corporate governance and responsible business practices.

What is Thrivent, and why does it matter for this fund?

Thrivent Financial is a financial services company with deep roots in faith communities, particularly among Lutherans and other Christian denominations across the American Midwest. It manages assets for individuals, institutions, and churches. That heritage shapes how Thrivent invests. The organization applies what it calls “values-based” screening to its funds, which means it excludes companies based on ESG (environmental, social, governance) considerations and its own ethical framework. This filtering is explicit and part of the fund’s prospectus, not an afterthought.

For an investor in TMVE, that screening is relevant context. The fund will not hold a company simply because it trades cheaply; it will also consider whether the company meets Thrivent’s governance standards and broader responsibility criteria. Some investors view this as a feature; others see it as an unnecessary constraint on returns. Either way, it is part of the fund’s identity, and potential holders should understand it before investing.

What does the fund hold, and how does it select stocks?

TMVE focuses on mid-cap stocks — companies roughly in the two-billion to ten-billion-dollar market-cap range. Within that space, Thrivent’s team looks for value: stocks trading at low multiples of earnings, book value, or cash flow, where the team believes the market is underpricing the company’s future earnings power or assets. A classic value stock is one where the balance sheet is clean, the earnings are stable, and the market has simply overlooked it due to temporary setbacks, unfashionable industry positioning, or limited analyst coverage.

The fund typically holds between 60 and 80 stocks, enough for meaningful diversification but concentrated enough that the best ideas carry real weight. Sectors vary based on where value opportunities appear. In some years the fund might lean toward beaten-down energy or financial companies; in others it might emphasize stable industrial or consumer discretionary names. The allocation shifts as relative valuations change.

How is this different from a pure value index fund?

An investor could simply buy a mid-cap value index ETF — say, one tracking the Russell Midcap Value Index — for a fraction of Thrivent’s fee. So the question is whether Thrivent’s active stock-picking and values-based screening justify the cost. The answer depends on two things: whether Thrivent’s analysts can genuinely identify mispriced mid-cap stocks, and whether the values-based exclusions improve returns, reduce risk, or simply satisfy an investor’s ethical commitments.

On the first point, Thrivent is a seasoned investment manager with decades of history. Its value approach is rooted in fundamental analysis, not momentum or technical trading. But active management is a mixed bag. Some funds beat their benchmarks regularly; many do not. On the second point, values-based screening can sometimes screen out companies that would have underperformed anyway (improving risk-adjusted returns) or exclude profitable but ethically questionable names (reducing future ESG-related volatility). But it can also exclude opportunities a pure value investor would have captured.

What are the real risks and constraints?

The first risk is selection risk. If Thrivent’s team misjudges which mid-caps are truly undervalued, the fund will underperform the mid-cap value index. This is the core risk of any active fund. The second risk is the value trap: a stock is cheap not because the market is irrational but because the business is deteriorating, the moat is eroding, or competition is intensifying. Value investors can catch many of these early, but not all.

The third risk is that value investing itself can underperform for extended periods. In eras when growth stocks and mega-caps dominate, mid-cap value funds tend to lag. An investor who bought TMVE in 2020 expecting steady returns watched it underperform between 2020 and 2024 as growth and tech dominated markets. Patience is required, and there is no guarantee the value cycle will favor TMVE’s holdings in any given year.

The fourth risk is specific to Thrivent’s values-based screening: it could exclude companies that would have been winners on valuation grounds alone. By filtering, Thrivent reduces the opportunity set, which is a feature if those exclusions improve outcomes but a cost if they do not. Over long periods, the impact is hard to measure because we cannot see what the fund would have owned if the screening were absent.

What should an investor focus on when researching TMVE?

How does it compare to its peers? Look at rolling returns versus pure mid-cap value index funds and other actively managed mid-cap value ETFs. Compare expense ratios. Ask whether Thrivent’s outperformance history (if any) is large enough to justify the fee.

What are the current holdings, and do they make sense? Download the fund’s holdings list from Thrivent’s website and spend time on the top ten positions. Do these look like genuinely undervalued businesses, or have they been value stocks for years with no improvement? A stock can be cheap and stay cheap if the underlying business does not improve.

Does the values-based screening matter to you? If ethical investing is central to your decision, that aligns naturally with TMVE. If you are purely optimizing for returns, ask whether the excluded companies would have helped or hurt.

What is Thrivent’s track record? Has this specific fund beaten the mid-cap value index over rolling 3-year, 5-year, and 10-year periods (net of fees)? Or has it lagged? The prospectus and fact sheets show this.

Ultimately, TMVE is for investors who believe (a) mid-cap value is an attractive opportunity, (b) Thrivent’s team can beat the index consistently, and (c) values-based screening either improves returns or aligns with their own ethical framework. If any of those beliefs is weak, a simpler, cheaper index fund may serve better.